Jazz Pharmaceuticals (JAZZ) Stock Rating Reconfirmed by Analysts at Wells Fargo; The $172.0 Target Indicates 29.50% Potential; Baldwin & Lyons Class B (BWINB) Shorts Up By 1.67%

November 8, 2017 - By Adrian Erickson

Among 21 analysts covering Jazz Pharmaceuticals (NASDAQ:JAZZ), 15 have Buy rating, 0 Sell and 6 Hold. Therefore 71% are positive. Jazz Pharmaceuticals has $229 highest and $124 lowest target. $181’s average target is 36.27% above currents $132.82 stock price. Jazz Pharmaceuticals had 56 analyst reports since August 3, 2015 according to SRatingsIntel. The firm has “Buy” rating by Deutsche Bank given on Monday, July 17. The stock has “Buy” rating by SunTrust on Monday, April 25. The rating was initiated by FBR Capital with “Buy” on Wednesday, October 18. The stock of Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) has “Buy” rating given on Monday, August 7 by RBC Capital Markets. Mizuho maintained the shares of JAZZ in report on Wednesday, February 24 with “Neutral” rating. The firm has “Neutral” rating by Janney Capital given on Thursday, August 25. Deutsche Bank maintained the stock with “Buy” rating in Wednesday, August 9 report. Mizuho maintained it with “Buy” rating and $152 target in Tuesday, February 21 report. The firm has “Outperform” rating given on Wednesday, October 14 by Northland Capital. The stock has “Neutral” rating by Mizuho on Thursday, April 6.

Baldwin & Lyons Class B (NASDAQ:BWINB) had an increase of 1.67% in short interest. BWINB’s SI was 60,900 shares in November as released by FINRA. Its up 1.67% from 59,900 shares previously. With 17,600 avg volume, 4 days are for Baldwin & Lyons Class B (NASDAQ:BWINB)’s short sellers to cover BWINB’s short positions. The SI to Baldwin & Lyons Class B’s float is 0.58%. It closed at $22.65 lastly. It is down 3.36% since November 8, 2016 and is downtrending. It has underperformed by 20.06% the S&P500.

Baldwin & Lyons, Inc. is a specialty property-casualty insurer providing liability coverage for large and medium-sized trucking and public transportation fleets, as well as coverage for trucking industry independent contractors. The company has market cap of $343.82 million. Through its divisions and subsidiaries, the Company engages in marketing and underwriting property and casualty insurance, including a limited assumption of risks as a reinsurer of other companies. It has a 105.39 P/E ratio. The Company’s divisions include property and casualty insurance, and reinsurance.

Investors sentiment decreased to 1.28 in 2017 Q2. Its down 0.45, from 1.73 in 2017Q1. It dived, as 8 investors sold Baldwin & Lyons Inc shares while 24 reduced holdings. 16 funds opened positions while 25 raised stakes. 7.02 million shares or 0.68% less from 7.07 million shares in 2017Q1 were reported. Deprince Race Zollo Inc holds 269,498 shares or 0.14% of its portfolio. Los Angeles Cap Equity Rech accumulated 36,581 shares. Moreover, Bankshares Of America Corporation De has 0% invested in Baldwin & Lyons Inc (NASDAQ:BWINB) for 75,268 shares. Rhumbline Advisers stated it has 11,895 shares or 0% of all its holdings. Nationwide Fund Advsrs holds 0% or 5,737 shares in its portfolio. Eagle Glob Advsr Ltd Limited Liability Company reported 16,285 shares. Legal And General Gru Inc Public Ltd Com, United Kingdom-based fund reported 2,617 shares. Public Employees Retirement Association Of Colorado reported 0% in Baldwin & Lyons Inc (NASDAQ:BWINB). Salem Counselors Inc stated it has 0% of its portfolio in Baldwin & Lyons Inc (NASDAQ:BWINB). Creative Planning reported 54 shares. Morgan Dempsey Capital Management Limited Liability Corp has invested 0.17% in Baldwin & Lyons Inc (NASDAQ:BWINB). First Quadrant Ltd Partnership Ca has invested 0% in Baldwin & Lyons Inc (NASDAQ:BWINB). Prudential Fincl Inc holds 0% or 15,599 shares in its portfolio. Morgan Stanley holds 104,883 shares. Franklin Resource Incorporated, California-based fund reported 271,048 shares.

It closed at $132.82 lastly. It is down 1.25% since November 8, 2016 and is uptrending. It has underperformed by 15.45% the S&P500.

Since May 9, 2017, it had 0 buys, and 2 sales for $780,130 activity. Shares for $30,596 were sold by MILLER MICHAEL PATRICK. $4.60M worth of Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) shares were sold by COZADD BRUCE C. On Tuesday, May 9 Hooper Suzanne Sawochka sold $400,000 worth of Jazz Pharmaceuticals plc – Ordinary Shares (NASDAQ:JAZZ) or 2,500 shares. Winningham Rick E sold $750,000 worth of stock.